Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
Keywords: 
Minimal residual disease (MRD)
Phenotypic profiles
Suitable method
Next-generation flow (NGF)
Issue Date: 
2019
Publisher: 
Ovid Technologies (Wolters Kluwer Health)
ISSN: 
2572-9241
Note: 
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)
Citation: 
Terpos, E. (Evangelos); Kostopoulos, I.V. (Ioannis V.); Kastritis, E. (Efstathios); et al. "Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy". HemaSphere. 3 (6), 2019, e300
Abstract
Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.

Files in This Item:
Thumbnail
File
Impact_of_Minimal_Residual_Disease_Detection_by.12.pdf
Description
Size
1.97 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.